Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-086645
Filing Date
2026-03-03
Accepted
2026-03-03 07:10:58
Documents
94
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K amlx-20251231.htm   iXBRL 10-K 3314242
2 EX-10.3 amlx-ex10_3.htm EX-10.3 37907
3 EX-21.1 amlx-ex21_1.htm EX-21.1 14828
4 EX-23.1 amlx-ex23_1.htm EX-23.1 3968
5 EX-31.1 amlx-ex31_1.htm EX-31.1 17886
6 EX-31.2 amlx-ex31_2.htm EX-31.2 17277
7 EX-31.3 amlx-ex31_3.htm EX-31.3 17875
8 EX-32.1 amlx-ex32_1.htm EX-32.1 10445
9 EX-32.2 amlx-ex32_2.htm EX-32.2 10206
10 EX-32.3 amlx-ex32_3.htm EX-32.3 9602
11 GRAPHIC img100680616_0.gif GRAPHIC 178818
  Complete submission text file 0001193125-26-086645.txt   13377026

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20251231.xsd EX-101.SCH 1852268
97 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20251231_htm.xml XML 2175359
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142 617-682-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-41199 | Film No.: 26711024
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)